Baird Maintains Outperform on IVERIC bio, Raises Price Target to $34
Baird analyst Colleen Kusy maintains IVERIC bio (NASDAQ:ISEE) with a Outperform and raises the price target from $27 to $34.
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Gainers
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.
Dow Tumbles Over 200 Points; ChannelAdvisor Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 200 points on Tuesday. All the three major indices recorded their third weekly loss in a row, with the Dow dropping around 3%, and the S&P 500 down around 3.3%.
Nasdaq Drops 100 Points; DWAC Shares Plummet
U.S. stocks traded lower midway through trading, with the Nasdaq dropping over 100 points on Tuesday. All the three major indices recorded their third weekly loss in a row, with the Dow dropping around 3%, and the S&P 500 down around 3.3%.
Why HyreCar Is Trading Higher By 60%, Here Are 63 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
HyreCar Inc. (NASDAQ: HYRE) jumped 60% to $1.2680 after the company announced it has received a $100 million revolving line of credit from a premier global investment bank and Medalist Partners.
$100 Invested In IVERIC bio 5 Years Ago Would Be Worth This Much Today
IVERIC bio (NASDAQ:ISEE) has outperformed the market over the past 5 years by 31.63% on an annualized basis producing an average annual return of 41.11%. Currently, IVERIC bio has a market capitalization of $1.73 billion.
Iveric Bio Shares Shoot Higher Following Positive Top-line Data From Late-Stage Geographic Atrophy Study
Iveric Bio (NASDAQ: ISEE) announced positive topline results from the second Phase 3 clinical trial of Zimura (avacincaptad pegol) for the treatment of geographic atrophy (GA).
Why Several Chinese Stocks Traded Higher; Here Are 58 Biggest Movers From Yesterday
Gainers
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) surged 95.3% to close at $0.2580 on Thursday after Ladenburg Thalmann initiated coverage on the stock with a Buy rating and announced a price target of $6.50.
